1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.

CAMPATH-1 antibodies have a long and successful history in the treatment of leukaemia, autoimmune disease and transplant rejection. The first antibody to undergo "humanisation", CAMPATH-1H, permits treatment with limited patient anti-globulin response. It recognises the CD52 antigen which...

Bibliográfalaš dieđut
Váldodahkkit:	James, L, Hale, G, Waldmann, H, Bloomer, A, Waldman, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1999

Geahča maid

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Dahkki: Cheetham, G, et al.
Almmustuhtton: (1998)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

The CAMPATH-1 antigen (CDw52).
Dahkki: Hale, G, et al.
Almmustuhtton: (1990)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

A personal history of the CAMPATH-1H antibody.
Dahkki: Waldmann, H
Almmustuhtton: (2002)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1996)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
Dahkki: Xia, M, et al.
Almmustuhtton: (1993)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Dahkki: Greenwood, J, et al.
Almmustuhtton: (1994)

COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H
Dahkki: Greenwood, J, et al.
Almmustuhtton: (1994)

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.
Dahkki: Xia, M, et al.
Almmustuhtton: (1991)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1995)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
Dahkki: Friend, P, et al.
Almmustuhtton: (1991)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
Dahkki: Dyer, M, et al.
Almmustuhtton: (1988)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
Dahkki: Naparstek, E, et al.
Almmustuhtton: (1999)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
Dahkki: Newman, D, et al.
Almmustuhtton: (1995)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

Campath-1H therapy in refractory ocular inflammatory disease.
Dahkki: Dick, A, et al.
Almmustuhtton: (2000)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
Dahkki: Rebello, P, et al.
Almmustuhtton: (1999)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1985)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1987)

In vivo 'purging' of residual disease in CLL with Campath-1H.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1997)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1986)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1985)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2004)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)